

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2006 (October 30, 2006)



ChemBio Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

<u>Nevada</u>	<u>000-30379</u>	<u>88-0425691</u>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3661 Horseblock Road, Medford, NY 11763
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (631) 924-1135

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- | | |
|--------------------------|--|
| <input type="checkbox"/> | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| <input type="checkbox"/> | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| <input type="checkbox"/> | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| <input type="checkbox"/> | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Item 7.01. Regulation FD Disclosure.

On October 30, 2006, the Company issued a press release entitled “Chembio Diagnostics to Present at 2006 C.E. Unterberg, Towbin Life Sciences Conference on October 31, 2006.” The press release is attached as Exhibit 99.1 hereto.

On October 31, 2006, certain officers of the Company will deliver an investor presentation that will include communication comprised of slides furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

On October 31, 2006, the Company issued a press release entitled “CORRECTING and REPLACING Chembio Diagnostics to Present at 2006 C.E. Unterberg, Towbin Life Sciences Conference on October 31, 2006.” The press release is attached as Exhibit 99.3 hereto.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
99.1	Press Release dated October 30, 2006
99.2	Investor Presentation for the Fourth Quarter of 2006
99.3	Press Release dated October 31, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 31, 2006

CHEMBIO DIAGNOSTICS, INC.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer



**ChemBio Diagnostics to Present at 2006 C.E. Unterberg, Towbin
Life Sciences Conference on October 31, 2006**

New York, October 30th, 2006--- ChemBio Diagnostics, Inc.'s (OTCBB:CEMI) Chairman and President, Lawrence Siebert, will present at the 2006 C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31st at 3:30 PM (EST) at the New York Palace Hotel in New York City. A live webcast of the presentation will be available on the Company's website at www.chembio.com, and will be available for 30 days. Additional information regarding the conference can be found at www.unterberg.com.

Mr. Siebert's presentation will include a discussion about ChemBio's recently announced marketing agreements as well as the opportunities for the Company's rapid diagnostic tests for infectious diseases. He will also highlight the positive impact that government funding, treatment goals, and CDC routine testing recommendations are having towards the worldwide demand for rapid HIV diagnostics.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

ABOUT C.E. UNTERBERG, TOWBIN

C.E. Unterberg, Towbin is committed to the emerging growth marketplace. We bring to bear our decades of experience working with promising technology innovators to provide sophisticated services and advice to emerging growth companies, their executives and investors.

Unterberg was formed in 1932 by Clarence Unterberg. In 1977 it merged with L.F. Rothschild to form L.F. Rothschild, Unterberg, Towbin. In 1990, the firm again became privately owned and independent when Clarence Unterberg's son, Thomas I. Unterberg, re-launched the firm as a full-service investment bank focused on emerging growth companies.

Today, Unterberg supplies capital and financial advice to emerging growth companies in the technology, health care and global security sectors. A relationship-driven bank, Unterberg is defined by its industry focus; a dedication to providing service by the senior members of the firm; its respected research team; global reach and perspective; and a commitment to serve the financial needs of tomorrow's industry leaders.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group 212-825-3210

Investors: James Carbonara

Media: Susan Morgenbesser

[EXHIBIT 99.2 - SEE PDF FORMAT](#)



CORRECTING and REPLACING Chembio Diagnostics to Present at 2006 C.E. Unterberg, Towbin Life Sciences Conference on October 31, 2006

NEW YORK--(BUSINESS WIRE)--First graph, first sentence, the presentation time should read: 3:00 PM (EST) sted: (3:30 PM (EST)).

The corrected release reads:

CHEMBIO DIAGNOSTICS TO PRESENT AT 2006 C.E. UNTERBERG, TOWBIN LIFE SCIENCES CONFERENCE ON OCTOBER 31, 2006

ChemBio Diagnostics, Inc.'s (OTCBB:[CEMI](#) - [News](#)) Chairman and President, Lawrence Siebert, will present at the 2006 C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31st at 3:00 PM (EST) at the New York Palace Hotel in New York City. A live webcast of the presentation will be available on the Company's website at www.chembio.com, and will be available for 30 days. Additional information regarding the conference can be found at www.unterberg.com.

Mr. Siebert's presentation will include a discussion about ChemBio's recently announced marketing agreements as well as the opportunities for the Company's rapid diagnostic tests for infectious diseases. He will also highlight the positive impact that government funding, treatment goals, and CDC routine testing recommendations are having towards the worldwide demand for rapid HIV diagnostics.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK[®] HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP(TM)), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

ABOUT C.E. UNTERBERG, TOWBIN

C.E. Unterberg, Towbin is committed to the emerging growth marketplace. We bring to bear our decades of experience working with promising technology innovators to provide sophisticated services and advice to emerging growth companies, their executives and investors.

Unterberg was formed in 1932 by Clarence Unterberg. In 1977 it merged with L.F. Rothschild to form L.F. Rothschild, Unterberg, Towbin. In 1990, the firm again became privately owned and independent when Clarence Unterberg's son, Thomas I. Unterberg, re-launched the firm as a full-service investment bank focused on emerging growth companies.

Today, Unterberg supplies capital and financial advice to emerging growth companies in the technology, health care and global security sectors. A relationship-driven bank, Unterberg is defined by its industry focus; a dedication to providing service by the senior members of the firm; its respected research team; global reach and perspective; and a commitment to serve the financial needs of tomorrow's industry leaders.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group

Investors:

James Carbonara, 212-825-3210

or

Media:

Susan Morgenbesser, 212-825-3210